Plozasiran sodium is under clinical development by Arrowhead Pharmaceuticals and currently in Phase III for Familial Chylomicronemia (Type I Hyperlipoproteinemia). According to GlobalData, Phase III drugs for Familial Chylomicronemia (Type I Hyperlipoproteinemia) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Plozasiran sodium LoA Report. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - Plozasiran Sodium in Familial Chylomicronemia (Type I Hyperlipoproteinemia)

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Plozasiran sodium overview

Plozasiran sodium (AROAPOC-3) is under development for the treatment of severe hypertriglyceridemia, mixed dyslipidemia and familial Chylomicronemia. It is administered through the subcutaneous route. The therapeutic candidate is a siRNA which acts by targeting apolipoprotein C III. It is being developed based on targeted RNAi molecule (TRiM) platform. It is a double-stranded oligomer ARO-APOC3 RNA interference-based liver targeted therapeutic.

See Also:

Arrowhead Pharmaceuticals overview

Arrowhead Pharmaceuticals (Arrowhead) is a biotech company that develops and commercializes gene silencing therapeutics. The company utilizes RNA chemistries and TRiM platform to target and silence disease-causing genes. Its pipeline products include ARO-AAT, ARO-APOC3, ARO-ANG3, ARO-PNPLA3, GSK4532990, ARO-C3, ARO-ENaC2, ARO-MUC5AC, ARO-RAGE, ARO-MMP7, ARO-COV, ARO-DUX4, ARO-SOD1, HZN-457, JNJ-3989 and Olpasiran. Arrowhead’s therapeutic areas include hypertriglyceridemia, dyslipidemia, facioscapulohumeral muscular dystrophy, complement-mediated diseases, much-obstructive or inflammatory pulmonary conditions, idiopathic pulmonary fibrosis, liver disease, gout, chronic hepatitis B and cardiovascular disease, among others. The company operates lab facilities in San Diego, California and Madison, Wisconsin, the US. Arrowhead is headquartered in Pasadena, California, the US.

For a complete picture of Plozasiran sodium’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 March 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.